{"analyses":[{"ciLowerLimit":"0.17","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"0.54","groupIds":["OG000"],"nonInferiorityComment":"No formal test, a confidence interval estimate for the grade 3+ treatment related AE rate.","nonInferiorityType":"OTHER","paramType":"grade 3+ treatment related AE rate","paramValue":"0.33"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"The adverse events and drug related toxicities will be summarized by grade using frequencies and relative frequencies. The rate of grade 3 or higher toxicities that are probably or definitely related to abatacept will be reported with 90% confidence intervals obtained using Jeffrey?s prior method.","groups":[{"description":"Patients receive abatacept IV over 30 minutes on day 1 of course 1, then SC on days 2, 8, 15, and 22 of course 1, and then on days 1, 8, 15, and 22 of subsequent courses. Patients also receive ixazomib citrate PO QD on days 1, 8, and 15 and dexamethasone on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAbatacept: Given IV and SC\n\nDexamethasone: Given PO\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Treatment (Abatacept, Ixazomib Citrate, Dexamethasone)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 30 days after last dose","title":"Incidence of Adverse Events Assessed Using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0","type":"SECONDARY","unitOfMeasure":"Participants"}